CTLA4 and melanoma: A total of 54.5% of the patients received immune checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors [22] and previous studies demonstrated that, even though the efficacy of these agents is significant on first primary melanomas, their interference with the development of second primary melanocytic malignant tumors or other non-cutaneous cancers remains controversial [22].